Park Ha Biological Technology Co., Ltd. (PHH)

PHH Income Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Revenue	1.94	2.46	1.92	0.93
Revenue Growth (YoY)	108.42%	28.12%	106.16%	-
Cost of Revenue	0.28	0.31	0.51	0.31
Gross Profit	1.66	2.15	1.41	0.62
Selling, General & Admin	0.96	0.78	1.15	1.12
Research & Development	0.03	0.03	0.06	-
Operating Expenses	1.06	0.97	1.21	1.12
Operating Income	0.6	1.18	0.2	-0.5
Interest Expense	-	-	-0	-0
Interest & Investment Income	0	0	0	0
Other Non Operating Income (Expenses)	-0	-0	-0.01	0.02
Pretax Income	0.6	1.18	0.19	-0.48
Income Tax Expense	0.2	0.33	-0	-
Net Income	0.4	0.85	0.19	-0.48
Net Income to Common	0.4	0.85	0.19	-0.48
Net Income Growth	-	345.40%	-	-
Shares Outstanding (Basic)	25	25	25	25
Shares Outstanding (Diluted)	25	25	25	25
EPS (Basic)	0.02	0.03	0.01	-0.02
EPS (Diluted)	0.02	0.03	0.01	-0.02
EPS Growth	-	345.45%	-	-
Free Cash Flow	0.16	0.1	1.43	-0.51
Free Cash Flow Per Share	0.01	0.00	0.06	-0.02
Gross Margin	85.36%	87.35%	73.47%	66.58%
Operating Margin	30.82%	48.01%	10.26%	-53.81%
Profit Margin	20.67%	34.65%	9.97%	-52.09%
Free Cash Flow Margin	8.38%	4.22%	74.52%	-54.86%
EBITDA	0.62	1.2	0.23	-0.46
EBITDA Margin	31.93%	48.82%	11.85%	-49.62%
D&A For EBITDA	0.02	0.02	0.03	0.04
EBIT	0.6	1.18	0.2	-0.5
EBIT Margin	30.82%	48.01%	10.26%	-53.81%
Effective Tax Rate	32.85%	27.89%	-	-
Advertising Expenses	-	0	0.01	0.04

Source: S&P Capital IQ. Standard template. Financial Sources.